Wealthspire Advisors LLC Raises Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Key Points

• Wealthspire Advisors LLC increased its stake in Regeneron Pharmaceuticals by 66.4%, acquiring an additional 3,731 shares, bringing their total to 9,350 shares worth approximately $5.93 million.
• A recent analysis shows that 83.31% of Regeneron's stock is owned by institutional investors, highlighting strong institutional interest in the company.
• Regeneron Pharmaceuticals reported $12.89 earnings per share for the last quarter, significantly exceeding expectations of $8.43, leading to a 3.6% year-over-year revenue increase.

Wealthspire Advisors LLC boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 66.4% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,350 shares of the biopharmaceutical company's stock after buying an additional 3,731 shares during the period. Wealthspire Advisors LLC's holdings in Regeneron Pharmaceuticals were worth $5,930,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in REGN. Capital International Investors lifted its holdings in shares of Regeneron Pharmaceuticals by 41.6% in the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock valued at $3,373,859,000 after acquiring an additional 1,390,534 shares during the last quarter. Dodge & Cox lifted its stake in shares of Regeneron Pharmaceuticals by 0.4% in the 4th quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company's stock valued at $1,653,543,000 after purchasing an additional 9,381 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Regeneron Pharmaceuticals by 63.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock valued at $1,485,527,000 after purchasing an additional 810,144 shares during the last quarter. Northern Trust Corp boosted its holdings in shares of Regeneron Pharmaceuticals by 14.8% in the 4th quarter. Northern Trust Corp now owns 1,054,829 shares of the biopharmaceutical company's stock worth $751,386,000 after purchasing an additional 136,184 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Regeneron Pharmaceuticals by 30.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 982,064 shares of the biopharmaceutical company's stock valued at $699,554,000 after purchasing an additional 226,952 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Guggenheim raised their price target on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. BMO Capital Markets raised their target price on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an "outperform" rating in a report on Monday. The Goldman Sachs Group dropped their price target on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. Wall Street Zen lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 1st. Finally, Cantor Fitzgerald began coverage on Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 target price for the company. One research analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $841.30.

Regeneron Pharmaceuticals Stock Up 0.6%

NASDAQ:REGN traded up $3.20 during mid-day trading on Friday, reaching $563.00. The company's stock had a trading volume of 1,024,297 shares, compared to its average volume of 969,491. The company has a quick ratio of 4.73, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,211.20. The stock has a fifty day moving average of $535.40 and a 200-day moving average of $600.61. The firm has a market capitalization of $60.78 billion, a PE ratio of 14.19, a price-to-earnings-growth ratio of 1.89 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business had revenue of $3,675,600 billion during the quarter, compared to analyst estimates of $3.30 billion. During the same quarter in the previous year, the business posted $11.56 EPS. The company's quarterly revenue was up 3.6% compared to the same quarter last year. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.